GHRS GH Research PLC — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$28.35

Period return

+11.61 (+69.35%)

Volume

152.2K

2026-07-21O $27.6 H $28.5 L $27.52 C $28.35MA5 $28.13MA20 $26.85MA60 $23.38MA120 $19.49

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 08. 06.Highin 16 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 05. 19.LowBUY2 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 05. 15.LowBUY2 months ago
Cantor Fitzgerald: Overweight
US analyst rating / recommendation change.
2026. 05. 15.LowBUY2 months ago
Citizens: Market Outperform
US analyst rating / recommendation change.
2026. 03. 06.LowBUY5 months ago
Citizens: Market Outperform
US analyst rating / recommendation change.
2026. 03. 06.LowBUY5 months ago
Needham: Buy
US analyst rating / recommendation change.
2026. 03. 02.LowBUY5 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 01. 24.LowBUY6 months ago
RBC Capital: Outperform
US analyst rating / recommendation change.
2026. 01. 07.LowBUY7 months ago
Canaccord Genuity: Buy
US analyst rating / recommendation change.
2026. 01. 06.LowBUY7 months ago
Needham: Buy
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $39.5 · 8 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

Sector: Healthcare
Industry: Biotechnology
HQ: Dublin, Ireland
Fiscal year end: —
Employees: 73
IPO date: —

View details →

GH Research PLC

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 19.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2026. 05. 15.	Cantor Fitzgerald	—	Maintain	Overweight → Overweight	—	Cantor Fitzgerald: Overweight
2026. 05. 15.	Citizens	—	Maintain	Market Outperform → Market Outperform	—	Citizens: Market Outperform
2026. 03. 06.	Citizens	—	Maintain	Market Outperform → Market Outperform	—	Citizens: Market Outperform
2026. 03. 06.	Needham	—	Maintain	Buy → Buy	—	Needham: Buy
2026. 03. 02.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy